Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Topical folinic acid enhances wound healing in rat model.

Duman N, Duman R, Tosun M, Akıcı M, Göksel E, Gökçe B, Alagöz O.

Adv Med Sci. 2018 Sep;63(2):347-352. doi: 10.1016/j.advms.2018.04.011. Epub 2018 Aug 6.

PMID:
30092503
2.

The effect of mammography screening regimen on incidence-based breast cancer mortality.

Yaffe MJ, Mittmann N, Alagoz O, Trentham-Dietz A, Tosteson AN, Stout NK.

J Med Screen. 2018 Dec;25(4):197-204. doi: 10.1177/0969141318780152. Epub 2018 Jul 26.

PMID:
30049249
3.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

PMID:
29554472
4.

The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update.

Alagoz O, Ergun MA, Cevik M, Sprague BL, Fryback DG, Gangnon RE, Hampton JM, Stout NK, Trentham-Dietz A.

Med Decis Making. 2018 Apr;38(1_suppl):99S-111S. doi: 10.1177/0272989X17711927.

PMID:
29554470
5.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

PMID:
29554468
6.

Contribution of Breast Cancer to Overall Mortality for US Women.

Gangnon RE, Stout NK, Alagoz O, Hampton JM, Sprague BL, Trentham-Dietz A.

Med Decis Making. 2018 Apr;38(1_suppl):24S-31S. doi: 10.1177/0272989X17717981.

PMID:
29554467
7.

Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, Huang X, Weaver DL, Burnside ES, Punglia RS, de Koning HJ, Lee SJ.

Med Decis Making. 2018 Apr;38(1_suppl):126S-139S. doi: 10.1177/0272989X17729358.

PMID:
29554463
8.

Cost-effectiveness of mammography from a publicly funded health care system perspective.

Mittmann N, Stout NK, Tosteson ANA, Trentham-Dietz A, Alagoz O, Yaffe MJ.

CMAJ Open. 2018 Feb 8;6(1):E77-E86. doi: 10.9778/cmajo.20170106.

9.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

10.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

11.

Effect of air bubbles localization and migration after embryo transfer on assisted reproductive technology outcome.

Fıçıcıoğlu C, Özcan P, Koçer MG, Yeşiladalı M, Alagöz O, Özkara G, Tayyar AT, Altunok Ç.

Fertil Steril. 2018 Feb;109(2):310-314.e1. doi: 10.1016/j.fertnstert.2017.10.032. Epub 2018 Jan 4.

PMID:
29306491
12.

Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.

Trentham-Dietz A, Ergun MA, Alagoz O, Stout NK, Gangnon RE, Hampton JM, Dittus K, James TA, Vacek PM, Herschorn SD, Burnside ES, Tosteson ANA, Weaver DL, Sprague BL.

Breast Cancer Res Treat. 2018 Feb;168(1):229-239. doi: 10.1007/s10549-017-4582-0. Epub 2017 Nov 28.

PMID:
29185118
13.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

PMID:
29150480
14.
15.

Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from Bahçeşehir Mammography Screening Project.

Özmen V, Gürdal SÖ, Cabioğlu N, Özcinar B, Özaydın AN, Kayhan A, Arıbal E, Sahin C, Saip P, Alagöz O.

Eur J Breast Health. 2017 Jul 1;13(3):117-122. doi: 10.5152/ejbh.2017.3528. eCollection 2017 Jul.

16.

Changes to physician and nurse time burdens when caring for patients under contact precautions.

Barker AK, Codella J, Ewers T, Dundon A, Alagoz O, Safdar N.

Am J Infect Control. 2017 May 1;45(5):542-543. doi: 10.1016/j.ajic.2017.01.026. Epub 2017 Mar 13.

17.

Pyrolysis of poppy capsule pulp for bio-oil production.

Hopa DY, Yılmaz N, Alagöz O, Dilek M, Helvacı A, Durupınar Ü.

Waste Manag Res. 2016 Dec;34(12):1316-1321. Epub 2016 Oct 19.

PMID:
27895286
18.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

19.

Cost-effectiveness of alternative colonoscopy surveillance strategies to mitigate metachronous colorectal cancer incidence.

Erenay FS, Alagoz O, Banerjee R, Said A, Cima RR.

Cancer. 2016 Aug 15;122(16):2560-70. doi: 10.1002/cncr.30091. Epub 2016 Jun 1.

20.

Reply to Koleva-Kolarova et al.

de Koning HJ, Alagoz O, Schechter CB, van Ravesteyn NT.

Breast. 2016 Jun;27:182-3. doi: 10.1016/j.breast.2016.01.005. Epub 2016 Mar 2. No abstract available.

PMID:
26946960
21.

Developing a utility decision framework to evaluate predictive models in breast cancer risk estimation.

Wu Y, Abbey CK, Chen X, Liu J, Page DC, Alagoz O, Peissig P, Onitilo AA, Burnside ES.

J Med Imaging (Bellingham). 2015 Oct;2(4):041005. doi: 10.1117/1.JMI.2.4.041005. Epub 2015 Aug 17.

22.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

23.

Total cost-effectiveness of mammography screening strategies.

Mittmann N, Stout NK, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Yaffe MJ.

Health Rep. 2015 Dec;26(12):16-25.

24.

Clinical outcomes of modelling mammography screening strategies.

Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK.

Health Rep. 2015 Dec;26(12):9-15.

25.

Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model.

Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK.

Health Rep. 2015 Dec;26(12):3-8.

26.

Cancer Models and Real-world Data: Better Together.

Kim JJ, Tosteson AN, Zauber AG, Sprague BL, Stout NK, Alagoz O, Trentham-Dietz A, Armstrong K, Pruitt SL, Rutter CM; Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium.

J Natl Cancer Inst. 2015 Nov 3;108(2). pii: djv316. doi: 10.1093/jnci/djv316. Print 2016 Feb.

27.

Using Active Learning for Speeding up Calibration in Simulation Models.

Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O.

Med Decis Making. 2016 Jul;36(5):581-93. doi: 10.1177/0272989X15611359. Epub 2015 Oct 15.

28.

Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.

Alagoz O, Durham D, Kasirajan K.

Pharmacogenomics J. 2016 Apr;16(2):129-36. doi: 10.1038/tpj.2015.39. Epub 2015 May 19.

PMID:
25987241
29.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

30.

The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.

Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, Trentham-Dietz A.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):905-12. doi: 10.1158/1055-9965.EPI-14-1286. Epub 2015 Mar 18.

31.

Developing a clinical utility framework to evaluate prediction models in radiogenomics.

Wu Y, Liu J, Del Rio AM, Page DC, Alagoz O, Peissig P, Onitilo AA, Burnside ES.

Proc SPIE Int Soc Opt Eng. 2015 Feb 21;9416. pii: 941617. Epub 2015 Mar 17.

32.

Opportunities for Operations Research in Medical Decision Making.

Tunc S, Alagoz O, Burnside E.

IEEE Intell Syst. 2014 May-June;29(3):59-62. No abstract available.

33.

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN.

Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

34.

Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts.

Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD.

Radiology. 2015 Mar;274(3):772-80. doi: 10.1148/radiol.14141237. Epub 2014 Oct 28.

35.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

36.

Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Rogowski W, Payne K, Schnell-Inderst P, Manca A, Rochau U, Jahn B, Alagoz O, Leidl R, Siebert U.

Pharmacoeconomics. 2015 Jan;33(1):49-59. doi: 10.1007/s40273-014-0211-5.

37.

An agent-based simulation model for Clostridium difficile infection control.

Codella J, Safdar N, Heffernan R, Alagoz O.

Med Decis Making. 2015 Feb;35(2):211-29. doi: 10.1177/0272989X14545788. Epub 2014 Aug 11.

38.

Predicting invasive breast cancer versus DCIS in different age groups.

Ayvaci MU, Alagoz O, Chhatwal J, Munoz del Rio A, Sickles EA, Nassif H, Kerlikowske K, Burnside ES.

BMC Cancer. 2014 Aug 11;14:584. doi: 10.1186/1471-2407-14-584.

39.

Pursuing optimal thresholds to recommend breast biopsy by quantifying the value of tomosynthesis.

Wu Y, Alagoz O, Vanness DJ, Trentham-Dietz A, Burnside ES.

Proc SPIE Int Soc Opt Eng. 2014 Mar 11;9037:90370U.

40.

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.

Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS.

J Natl Cancer Inst. 2014 May 28;106(6):dju092. doi: 10.1093/jnci/dju092. Print 2014 Jun.

41.
42.

A comprehensive methodology for determining the most informative mammographic features.

Wu Y, Alagoz O, Ayvaci MU, Munoz Del Rio A, Vanness DJ, Woods R, Burnside ES.

J Digit Imaging. 2013 Oct;26(5):941-7. doi: 10.1007/s10278-013-9588-5.

43.

Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis.

Batina NG, Trentham-Dietz A, Gangnon RE, Sprague BL, Rosenberg MA, Stout NK, Fryback DG, Alagoz O.

Breast Cancer Res Treat. 2013 Apr;138(2):519-28. doi: 10.1007/s10549-013-2435-z. Epub 2013 Feb 16.

44.

Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.

Ayvaci MU, Shi J, Alagoz O, Lubner SJ.

Med Decis Making. 2013 May;33(4):521-32. doi: 10.1177/0272989X12470755. Epub 2013 Jan 11.

45.

What is the optimal threshold at which to recommend breast biopsy?

Burnside ES, Chhatwal J, Alagoz O.

PLoS One. 2012;7(11):e48820. doi: 10.1371/journal.pone.0048820. Epub 2012 Nov 7.

46.

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force.

Value Health. 2012 Sep-Oct;15(6):812-20. doi: 10.1016/j.jval.2012.06.014.

47.

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM.

Med Decis Making. 2012 Sep-Oct;32(5):690-700.

PMID:
22990084
48.

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ.

Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002.

49.

The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions.

Ayvaci MU, Alagoz O, Burnside ES.

Manuf Serv Oper Manag. 2012 Apr;14(4):600-617.

50.

Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors.

Chhatwal J, Alagoz O, Burnside ES.

Oper Res. 2010 Nov 1;58(6):1577-1591.

Supplemental Content

Loading ...
Support Center